3 Promising Undervalued Small Caps With Insider Activity In October 2026
Over the last 7 days, the United States market has experienced a 1.6% drop, though it remains up by 12% over the past year with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying promising small-cap stocks with notable insider activity can be crucial for investors seeking opportunities that may not yet be fully recognized in the broader market.
Top 10 Undervalued Small Caps With Insider Buying In The United States
| Name | PE | PS | Discount to Fair Value | Value Rating |
|---|---|---|---|---|
| Regional Management | 6.6x | 0.5x | 30.34% | ★★★★★★ |
| Bank of Marin Bancorp | NA | 6.9x | 35.44% | ★★★★★☆ |
| Financial Institutions | 9.4x | 3.1x | 26.99% | ★★★★★☆ |
| Surgery Partners | NA | 0.6x | 22.69% | ★★★★★☆ |
| Five Star Bancorp | 14.5x | 6.2x | 47.23% | ★★★★☆☆ |
| Union Bankshares | 9.3x | 2.0x | 45.97% | ★★★★☆☆ |
| German American Bancorp | 12.9x | 4.8x | 26.88% | ★★★☆☆☆ |
| Tennant | 61.2x | 0.9x | 20.86% | ★★★☆☆☆ |
| Orion Group Holdings | 96.7x | 0.4x | 48.67% | ★★★☆☆☆ |
| Chain Bridge Bancorp | 12.0x | 4.9x | 48.63% | ★★★☆☆☆ |
Underneath we present a selection of stocks filtered out by our screen.
Orchestra BioMed Holdings (OBIO)
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Orchestra BioMed Holdings focuses on developing and commercializing innovative therapeutic solutions in the surgical and medical equipment sector, with a market cap of approximately $0.22 billion.
Operations: Orchestra BioMed Holdings generates revenue primarily from its Surgical & Medical Equipment segment, with recent figures showing $31.98 million. The company's cost of goods sold is relatively low at $0.157 million, resulting in a high gross profit margin of 99.51%. Despite this, the company faces significant operating expenses, notably in research and development and general and administrative areas, impacting its net income negatively.
PE: -5.7x
Orchestra BioMed Holdings, a small company in the U.S., is drawing attention for its innovative AVIM Therapy, which aims to address hypertension in pacemaker patients. Despite reporting a net loss of US$23.76 million in Q2 2026 and a revenue drop to US$0.088 million, insider confidence remains high with recent purchases indicating belief in future potential. The company's strategic partnership with Medtronic and successful trial enrollment could position it well for growth despite current financial challenges.
- Click to explore a detailed breakdown of our findings in Orchestra BioMed Holdings' valuation report.
Understand Orchestra BioMed Holdings' track record by examining our Past report.
Financial Institutions (FISI)
Simply Wall St Value Rating: ★★★★★☆
Overview: Financial Institutions operates primarily in the banking sector with additional income from investment advisory services, and has a market capitalization of approximately $0.3 billion.
Operations: The company generates revenue primarily from banking services, with a notable contribution from investment advisory income. Operating expenses are predominantly driven by general and administrative costs, which reached $123.34 million in the latest period. The net income margin has shown variability, peaking at 36.31% before experiencing fluctuations in subsequent periods.
PE: 9.4x
Financial Institutions, a small player in the U.S. market, appears undervalued with steady financial growth. In the second quarter of 2026, net interest income rose to US$53.36 million from US$49.12 million a year prior, while net income increased to US$21.18 million from US$17.53 million. Insider confidence is evident as board members have shown commitment by purchasing shares in recent months, signaling potential value recognition internally despite no recent buybacks between April and June 2026.
Tennant (TNC)
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Tennant is engaged in the design, manufacture, and sale of products used in the maintenance of nonresidential surfaces with a market cap of approximately $1.38 billion.
Operations: The company generates revenue primarily from the design, manufacture, and sale of products used in the maintenance of nonresidential surfaces, with recent quarterly revenue reaching $1.22 billion. The cost of goods sold (COGS) for the same period was $745.1 million, resulting in a gross profit margin of 38.77%. Operating expenses include significant allocations towards general and administrative costs and research and development activities. Net income for the latest quarter stood at $18.3 million, reflecting a net income margin of 1.50%.
PE: 61.2x
Tennant, a smaller player in the U.S. market, recently showcased insider confidence as an independent director acquired 8,163 shares for nearly US$500K. This move underlines potential value recognition internally despite challenges like declining net income and profit margins dropping to 1.5% from last year's 4.8%. Although earnings per share fell significantly year-over-year, Tennant raised its full-year sales guidance to US$1.27 billion-US$1.31 billion, suggesting optimism about future growth prospects amidst financial restructuring efforts and strategic leadership transitions.
- Dive into the specifics of Tennant here with our thorough valuation report.
Gain insights into Tennant's past trends and performance with our Past report.
Seize The Opportunity
- Click through to start exploring the rest of the 64 Undervalued US Small Caps With Insider Buying now.
- Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
- Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
Contemplating Other Strategies?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com